The most common grade @ or @ adverse events in the palbociclib-fulvestrant group were neutropenia ( @ % , vs. @ % in the placebo-fulvestrant group ) , leukopenia ( @ % vs. @ % ) , anemia ( @ % vs. @ % ) , thrombocytopenia ( @ % vs. @ % ) , and fatigue ( @ % vs. @ % ) .